Epirubicin, Paclitaxel, and Etoposide for Small-Cell Lung Cancer
Author Information
Author(s): Tibaldi C, Prochilo T, Russo F, Pennucci M C, Del Freo A, Innocenti F, Fabbri A, Falcone A, Conte P F, Baldini E
Primary Institution: Division of Medical Oncology, Civil Hospital, Livorno, Italy
Hypothesis
The study aimed to evaluate the feasibility and toxicity of escalating doses of epirubicin and paclitaxel plus a fixed dose of etoposide in extensive disease small-cell lung cancer.
Conclusion
The triplet of epirubicin, paclitaxel, and etoposide showed high antitumor activity with mild nonhaematological side effects in patients with extensive-stage small-cell lung cancer.
Supporting Evidence
- Seven out of 19 evaluable patients achieved a complete response (37%).
- Nineteen patients had an overall response rate of 84.2%.
- Febrile neutropenia was documented in seven episodes.
- Median time to progression was 6 months.
- Median overall survival was 13 months.
Takeaway
Doctors tested a new combination of three cancer drugs to see if they could help patients with a tough type of lung cancer, and it worked well for many of them.
Methodology
The study involved a phase I/II trial with chemotherapy-naïve patients, evaluating maximum tolerated doses and response rates.
Potential Biases
Potential bias due to the non-randomized nature of the trial and the involvement of multiple institutions.
Limitations
The study was limited by the small sample size and the lack of a control group.
Participant Demographics
Median age was 62 years, with a range of 50-70 years; the majority had two or more metastatic sites.
Statistical Information
Confidence Interval
95% CI=60.4–96.6
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website